Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Rang in Aktien #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Aktienkurs
$4.74
Zuletzt synchronisiert: 2026-08-31
Marktkapitalisierung
$372.19M
Veränderung (1 Tag)
-2.47%
Veränderung (1 Jahr)
-1.04%
Land
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategorie

Kursverlauf für Lexeo Therapeutics, Inc. Common Stock (LXEO)
Höchster Schlusskurs: $4.91 am 2026-08-01

Niedrigster Schlusskurs: $11.06 am 2023-11-01
Kursverlauf der Aktie von Lexeo Therapeutics, Inc. Common Stock von 2023 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$747.04 4.70%
CH